EF Hutton Initiates Coverage On Can Fite Biofarma with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Can Fite Biofarma (AMEX:CANF) with a Buy rating and a price target of $10, as announced by analyst Jason Kolbert.

July 17, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on Can Fite Biofarma with a Buy rating and a price target of $10, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $10 by a reputable analyst from EF Hutton is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100